ERBB3 and head and neck squamous cell carcinoma: While the activity of Cetuximab is complex, and is well established to involve both signaling and immunologic mechanisms, neither of the ErbB3 antibodies possess immunologic activity19,26 suggesting that antibody-mediated ErbB3 inhibition was sufficient to suppress growth of HNSCC PDXs established from multiple anatomic subsites.